Cebranopadol effects on ventilatory drive, central nervous system, and pain (IASP 2024) - Jul 18, 2024 - Abstract #WE494; Pres time: Aug 7, 2024; 09:30 AM - 11:00 AM; Location: Exhibition Hall/Poster Area; "This study confirms that cebranopadol produces potent analgesia that will persist for longer and will be associated with less respiratory depression when compared to equianalgesic doses of oxycodone.The delayed onset of respiratory effects is a noteworthy clinical benefit of cebranopadol, allowing for the gradual accumulation of arterial CO2, thereby mitigating the full manifestation of respiratory depression. This characteristic of cebranopadol both gives the body time to adjust its breathing and gives healthcare providers a more extended timeframe for appropriate interventions, strengthening its overall safety in clinical use. Taken together, the results of this and previous clinical studies, as well as results from preclinical models, provide evidence to support the likelihood a ceiling of respiratory depression exists in humans."
Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|
|
Simone Jansen; Antonio Pardo, MD; Joseph Greico, PhD; James Hackworth, PhD; Albert Dahan, MD, PhD
|